Harvard Bioscience, Inc. (HBIO) has a consensus analyst rating of Buy, based on 5 analysts covering the stock. Of those, 4 recommend buying, 1 recommend holding, and 0 recommend selling.
The analyst consensus price target for HBIO is $0.60, representing a -89.5% downside from the current price of $5.74. Price targets range from a low of $0.60 to a high of $0.60.
